Drug Profile
Zidebactam - Wockhardt
Alternative Names: WCK-5107Latest Information Update: 28 May 2021
Price :
$50
*
At a glance
- Originator Wockhardt
- Class Antibacterials; Azabicyclo compounds; Piperidines; Small molecules; Sulfoxides
- Mechanism of Action Penicillin-binding protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 28 May 2021 No recent reports of development identified for phase-I development in Bacterial-infections(Combination therapy, In volunteers) in USA (IV)
- 28 May 2021 No recent reports of development identified for phase-I development in Bacterial-infections(Monotherapy, In volunteers) in USA (IV)
- 13 Apr 2019 Zidebactam is still in phase I trials for Bacterial infections in USA